Anixa Biosciences Inc
NASDAQ:ANIX
Anixa Biosciences Inc
NASDAQ:ANIX
Price:
2.77
USD
-4.15%
Market Closed
Market Cap:
$92.5m
Relative Value
The Relative Value of one
ANIX
stock under the Base Case scenario is
0.06
USD.
Compared to the current market price of 2.77 USD,
Anixa Biosciences Inc
is
Overvalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ANIX
Relative Value
Base Case
0.06
USD
Overvaluation 98%
Multiples Across Competitors
ANIX Competitors Multiples
Anixa Biosciences Inc Competitors
Anixa Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Anixa Biosciences Inc
NASDAQ:ANIX
|
92.7m USD | 0 | -9 | -7.1 | -7.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.3B USD | 6 | 88 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.4B USD | 5.2 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 6 | 20.6 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.7B USD | 9.6 | 29 | 21.8 | 22.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.5 | 17.5 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
64.8B AUD | 3 | 32.9 | 11 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.4B EUR | 10.3 | 33.2 | 35.8 | 36.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
